IMAGE

Fig. 2

ID: ZDB-IMAGE-211009-29
Publication: He et al., 2021 - Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss
All Figures: Figures for He et al., 2021

Image

Figure Caption

Fig. 2 mTOR inhibitors achieve a durable antitumor effect in <italic>nf1/pten</italic>-mutant melanoma.

a Schematic of the melanoma tumor transplantation assay. b, c Transplanted nf1/pten-mutant melanoma tumor cells were monitored daily in 3-week-old rag2^−/− recipient zebrafish treated with DMSO (CTR; n = 12), 80 nM trametinib (n = 11), 2 μM buparlisib (n = 11), or the combination of 80 nM trametinib and 2 μM buparlisib (n = 12) for 6 days. Kaplan–Meier curves for progression-free survival (PFS, b) and overall survival (OS, c) are shown. Statistical analyses were performed by log-rank test, comparing drug-treated with DMSO-treated zebrafish. d, e Transplanted nf1/pten-mutant melanoma tumor cells were monitored daily in 3-week-old rag2^−/− recipient zebrafish treated with DMSO (CTR; n = 12, same values as in b, c), 20 μM sirolimus (n = 12), 20 μM everolimus (n = 11) or 40 μM temsirolimus (n = 11) for 6 days. Kaplan–Meier curves are shown, with statistical analyses performed as in b, c. For all experiments involving drug treatments, drugs were replenished every 2 days during the 6-day course of treatment (black arrows).

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene